Wittkopp competitive analysis

Explore patent oppositions filed by Wittkopp against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Mar 12, 2026
Patent NumberTitleApplicantOpposition Date
Methods Of Treatment Of Cholestatic DiseasesGENFITJan 29, 2026
Manufacture Of A Crystalline Pharmaceutical ProductORIONJan 8, 2026
Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-DioneAMGEN EUROPEDec 19, 2025
Solid State Forms Of Ixazomib CitrateASSIA CHEMICAL INDUSTRIESDec 19, 2025
Methods For Treating Hypertrophic CardiomyopathyCYTOKINETICSOct 14, 2025
Pharmaceutical Composition, Methods For Treating And Uses ThereofBOEHRINGER INGELHEIMSep 16, 2025
Sodium (2R, 5S, 13Ar) -7, 9-Dioxo-10- ( (2,4,6-Trifluorobenzyl) Carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13A-Octahydro-2, 5-Methanopyrido [1',2' : 4.5] Pyrazino [2, 1-B] Oxazepin-8-OlateGILEAD SCIENCESSep 2, 2025
Pharmaceutical FormulationsGILEAD SCIENCESSep 2, 2025
Processes For Preparing Jak Inhibitors And Related Intermediate CompoundsINCYTEAug 12, 2025
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 23, 2025

Latest PTAB cases involving Wittkopp

Discover the latest PTAB cases involving Wittkopp, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Wittkopp with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Mar 12, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
WITTKOPP10 - - -
ASTRAZENECA - 27 - 18
BRISTOL MYERS SQUIBB IRELAND - 43 - -
BRISTOL MYERS SQUIBB IRELAND UNLIMITED - 43 - -